Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02227251
Title Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Karyopharm Therapeutics, Inc
Indications

diffuse large B-cell lymphoma

Therapies

Selinexor

Age Groups: adult
Covered Countries USA | ITA | FRA | ESP | DEU | CAN | BEL | AUT


No variant requirements are available.